Pharmacological characterization of YM471, a novel potent vasopressin V 1A and V 2 receptor antagonist

By Tsukada J.   Tahara A.   Tomura Y.   Wada K.-i.   Kusayama T.   Ishii N.   Aoki M.   Yatsu T.   Uchida W.   Taniguchi N.   Tanaka A.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 129-138

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V 1A and V 2 receptor antagonist, in dogs

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Tsukada J.   Uchida W.   Tanaka A.   Takenaka T.  

European Journal of Pharmacology, Vol. 321, Iss. 2, 1997-02 ,pp. : 225-230

Elsevier

Access to resources Recommend Favorite

The behavioral effect of vasopressin in the ventral hippocampus is antagonized by an oxytocin receptor antagonist

By Paban V.   Alescio-Lautier B.   Devigne C.   Soumireu-Mourat B.  

European Journal of Pharmacology, Vol. 361, Iss. 2, 1998-11 ,pp. : 165-173

Elsevier

Access to resources Recommend Favorite

Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V 1 receptor antagonist in mice

By Alescio-Lautier B.   Rao H.   Paban V.   Devigne C.   Soumireu-Mourat B.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 763-770

Elsevier

Access to resources Recommend Favorite

Angiotensin AT 1 receptor-mediated vasopressin release and drinking are potentiated by an AT 2 receptor antagonist

By Hohle S.   Spitznagel H.   Rascher W.   Culman J.   Unger T.  

European Journal of Pharmacology, Vol. 275, Iss. 3, 1995-03 ,pp. : 277-282

Elsevier

Access to resources Recommend Favorite